Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Hunk as aregulator of TNBC genes involve in tumor immunity

ABSTRACT: The goal of this study was to target tumor immune specific genes and allowed us to specifically immune profiling what genes are change in HUNK or HUNK knockdown groups. A main objective was to determine if genes related to the citokine signaling pathway were changed in HUNK control compared to HUNK knockdown groups.

ORGANISM(S): Mus musculus

PROVIDER: GSE242859 | GEO | 2024/06/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

HSL119 results in gene expression changes equivalent to HUNK shRNA

Project description:The goal of this study was to determine the gene similarities and overlap between human HER2+ breast cancer cells treated with a HUNK inhibitor (HSL119) and samples engineered with HUNK shRNA (KD1 and KD2). A main objective was to determine if genes related to the AKT pathway were changed in HUNK treated or HUNK knockdown groups compared to control.

2023-12-05 | GSE233608 | GEO

Hunk as aregulator of TNBC genes involve in tumor immunity

Project description:Hunk as aregulator of TNBC genes involve in tumor immunity

| PRJNA1015176 | ENA

Project description:We previously identified a novel SNF1/AMPK-related protein kinase, Hunk, from a mammary tumor arising in an MMTV-neu transgenic mouse. The function of this kinase is unknown. Using targeted deletion in mice, we now demonstrate that Hunk is required for the metastasis of c-myc-induced mammary tumors, but is dispensable for normal development. Reconstitution experiments revealed that Hunk is sufficient to restore the metastatic potential of Hunk-deficient tumor cells, as well as defects in migration and invasion, and does so in a manner that requires its kinase activity. Consistent with a role for Hunk in the progression of human cancers, the human homologue of Hunk is overexpressed in aggressive subsets of carcinomas of the ovary, colon, and breast. In addition, a murine gene expression signature that distinguishes Hunk-wild type from Hunk-deficient mammary tumors predicts clinical outcome in women with breast cancer. Together, these findings establish a role for Hunk in metastasis and an in vivo function for this kinase. Hunk-deficient animals were crossed to mice harboring an MMTV-c-myc transgene (Leder et al., 1986). Hunk heterozygous, MMTV-c-myc mice were backcrossed to Hunk heterozygous animals. MMTV-c-myc female animals of each Hunk genotype were mated twice, then monitored twice weekly for mammary tumors. Mice possessing tumors with a maximum diameter of 20 mm were sacrificed and organs were examined at necropsy. Tumor nodules were identified by examination of organs through a Leica Wild MZ8 dissection microscope.

2009-12-31 | E-GEOD-14226 | biostudies-arrayexpress

2009-12-31 | GSE14226 | GEO

Hypoxia inhibits HUNK-mediated phosphorylation of GEF-H1 for epithelial-to-mesenchymal transition

Project description:Hypoxia regulates epithelial to mesenchymal transition (EMT) of cancer cells. However, the mechanism underlying hypoxia-mediated EMT remains largely unknow. Here, utilizing colorectal cell carcinoma (CRC) as a model, we find that HUNK inhibits EMT and suppresses metastasis of CRC cells via its substrate GEF-H1 in a kinase-dependent manner. Mechanistically, HUNK directly phosphorylates GEF-H1 at ser645 site, which activates RhoA and consequently leads to a cascade of phosphorylation of LIMK1/CFL-1, thereby stabilizing F-actin and inhibiting EMT. Moreover, hypoxia suppresses HUNK activity and dephosphorylates GEF-H1 to promote EMT. Clinically, the expression levels of both HUNK and phosphorylation of GEH-H1 ser645 are not only downregulated in CRC tissues with metastasis compared to that without metastasis, but also positively correlated among these tissues. Our findings highlight the importance of hypoxia-regulated HUNK kinase activity and phosphorylation of GEF-H1 in regulation of EMT and metastasis of CRC.

2022-05-27 | GSE203440 | GEO

lncSLERT promotes liver metastasis in colorectal cancer by down-regulating HUNK expression via RBM15-mediated m6A modification

Project description:Metastasis constitutes a hallmark of cancer and serves as the principal cause of cancer-related mortality. Nevertheless, the mechanism of liver metastasis in CRC remains incompletely clarified. This study investigates the long non-coding RNA (lncRNA) SLERT and its critical role in promoting liver metastasis of colorectal cancer (CRC) by downregulating HUNK expression. We found that SLERT was significantly upregulated in CRC tissues, correlating with poorer survival outcomes. Functional assays revealed that silencing SLERT inhibited CRC cell migration and invasion, while its overexpression promoted these metastatic behaviors. Mechanistic analysis showed that SLERT interacts with the RNA-binding protein RBM15, impairing its ability to stabilize HUNK mRNA, leading to decreased HUNK levels and increased metastatic potential. The cytoplasmic localization of SLERT indicates its active role in regulating gene expression within the tumor microenvironment. Collectively, these results suggest that SLERT serves as a potential diagnostic biomarker and therapeutic target, indicating that targeting SLERT or restoring HUNK expression could provide novel strategies to combat liver metastasis in CRC and improve patient prognosis.

2025-01-01 | GSE284657 | GEO

HSL119 results in gene expression changes equivalent to HUNK shRNA

Project description:HSL119 results in gene expression changes equivalent to HUNK shRNA

| PRJNA976742 | ENA

Project description:sequencing of HUNK knockdown SW480 cells

| PRJNA590069 | ENA

Hypoxia inhibits HUNK-mediated phosphorylation of GEF-H1 for epithelial-to-mesenchymal transition

Project description:Hypoxia inhibits HUNK-mediated phosphorylation of GEF-H1 for epithelial-to-mesenchymal transition

| PRJNA840881 | ENA

The impact of PD-1 antibody or G-CSF antibody on the immune system and the hematopoiesis of TNBC mice

Project description:Triple negative breast cancer (TNBC) is the most intractable subtype of breast cancer. Inhibitors of programmed cell death protein-1 (PD-1) or its ligand PD-L1 have been considered as promising treatment for TNBC patients. However, only a minor subset of TNBC patients benefits from the monotherapy. An analysis of how PD-1/PD-L1 blockage affect immune activities in TNBC tumor-bearing mice could provide insights for it limitation. G-CSF was known to be highly elevated in TNBC cells, and affecting hematopoiesis and the immune system. Spleen is an immune organ and with extramedullary hematopoiesis in TNBC mice. Here we analyzed splenocyte gene expressions changed by administration of either PD-1 antibody or G-CSF antibody in both 4T1 tumor bearing mice and non-tumor control mice. TNBC tumor significantly changed gene expressions in splenocytes, which is consistent with a significant change in splenocyte composition. These genes were enriched in immune related pathways. Anti-PD-1 antibody treatment had limited impact on spleen immune cells composition and splenocyte gene expressions. The most affected genes were enriched in metabolism and extracellular matrix related pathways. Anti-G-CSF antibody treatment had higher impact on the splenocyte gene expression profile, making it more like the gene expression profile in the non-tumor control mice.

2023-03-13 | GSE226999 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data